Trial of Ridaforolimus in Sarcoma Patients Meets Primary Endpoint of Improved Progression-Free Survival

The results of the Phase 3, placebo-controlled SUCCEED trial, which evaluated the oral mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy, have shown that the primary endpoint of progression-free survival has been met to maintain the benefit of prior chemotherapy, as reported at the American Society of Clinical Oncology's 2011 ...

Sign In to MPR

Sign in with your MPR account

Keep me signed in Forgot your password?

Don't have one of these accounts?

Create an account for free »

Register for free with MPR

REGISTER FOR FREE WITH A MPR ACCOUNT

Registration acknowledges the Terms and Conditions and Privacy Policy

Already have an account?

Log in now »

FORGET YOUR PASSWORD?

Enter your MPR registration email address to receive a new password.

NEW PASSWORD SENT

Already have an account?

Log in now »

ALMOST DONE

Almost Done

Please confirm the information BELOW before Signing In

By registering you agree with our Terms and Conditions and Privacy Policy.

« CANCEL AND GO BACK

Thank you for registering with MPRxOnline.

Please take a moment to tell us a little more about yourself, so we can bring you specialized clinical content that’s most valuable to you.

NEED HELP? Contact Customer Service »